1. South Africa is facing a major shortfall in global health aid funding after the U.S. announced its withdrawal from the World Health Organization and suspended USAID foreign aid in 2025, with several European countries following suit. [para. 1][para. 2] The government and researchers at Wits University estimate an aid-funding gap of more than $440 million, leading to over 8,000 healthcare workers losing their jobs and clinic closures. Research funding is short by more than $400 million, putting at least 27 HIV trials and 20 TB trials at risk. [para. 3] While the South African government has committed some funds, it urgently needs cheaper, more innovative products to navigate the financing crunch. [para. 4]
2. Chinese in-vitro diagnostics companies are beginning to gain traction in this environment. Pluslife Biotech introduced MiniDock, a palm-size testing device that runs on a power bank and is easy to deploy in communities, while Hugo Biotech brought EASY-LAB, designed for high-volume TB screening. [para. 5] Compared with existing products, these systems are less expensive and can use tongue-swab samples, potentially supporting South Africa's campaign to end tuberculosis by 2035. [para. 6]
3. Entering the international public health procurement market is challenging for Chinese firms. They need global research data, inclusion in WHO treatment guidelines, and WHO prequalification (PQ) certificates. [para. 7] Even after obtaining certification, they face uncertainty as recipient governments must still place orders and allocate budgets, which has led many Chinese businesses to stay on the sidelines, leaving the market dominated by European, U.S., and Indian companies. [para. 8]
4. Some innovators now design products from the outset around global public health needs, using financing from nonprofits like the Gates Foundation to conduct global multicenter studies and gather real-world evidence. [para. 9] This approach provides a stronger evidence base when seeking WHO recommendations and PQ certification, improving their chances of acceptance. [para. 10]
5. A case study, the ACT-TB study led by physician Jeanne Coetzee in Johannesburg, used mobile testing vans and two palm-size MiniDock devices. [para. 11][para. 12] Over seven months, the team screened 6,011 participants and identified 51 positive TB cases, a positivity rate of 0.85%, far exceeding the expected 0.2%. [para. 21][para. 22] MiniDock is the only product in the WHO's near-point-of-care (NPOC) molecular-diagnostics category. [para. 14] The Global Tuberculosis Report estimated 10.7 million new TB cases in 2024, but only 8.3 million were reported, highlighting more than one-fifth of patients going undetected. [para. 16]
6. The testing process is highly efficient; participants spend roughly 15 to 20 minutes from entry to completion, compared to several hours at traditional clinics. [para. 18][para. 19][para. 20] South Africa has launched an End TB campaign, aiming to raise annual testing capacity from 3.6 million to five million people and to diagnose 250,000 new cases during 2025 and 2026. [para. 30]
7. Pluslife invested heavily with Gates Foundation support, completing global multicenter clinical studies within roughly a year from mid-2024 to early 2026. [para. 31][para. 36] The company secured procurement orders and regulatory access in 12 countries, including South Africa. [para. 38] On June 16, the Global Fund announced it would deploy the testing system across 13 countries, providing nearly three million tests with procurement worth about $13 million. [para. 39]
8. Hugo Biotech complements MiniDock by focusing on mass screening of high-risk populations. South Africa has 174 first-tier molecular laboratories, each equipped with two BD Max machines that test 24 sputum samples in 4.5 to 5 hours. [para. 42][para. 43] Hugo's EASY-LAB can test 48 samples at once—twice the capacity of BD Max—is fully automated, uses tongue swabs, and can run on general-purpose PCR machines used during Covid. [para. 44][para. 45] It is working with the Wits Diagnostic Innovation Hub for local regulatory approval. [para. 46]
9. China still has a small share of the global public health procurement market. In 2024, UNICEF's global procurement reached $5.61 billion, with the U.S. as the top supplier at $770 million, while China ranked ninth at $190 million. [para. 48][para. 49] Traditional companies face PQ certification costs of tens of millions of dollars with no guaranteed orders, so many decide the risk isn't worth taking. [para. 54]
10. Companies now testing this path want more government support. They suggest establishing green channels for customs and cold-chain logistics to reduce export costs, and stronger national backing through bilateral cooperation and Chinese overseas health-aid projects. [para. 56][para. 57][para. 58][para. 59]
AI generated, for reference only
Sign in with Google
Sign in with Facebook
Sign in with 财新